Please assess the completion status of the following clinical trial:

Trial Title: Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Volunteer~* Willing and able to give informed consent~* Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic~* Male and female subjects aged 18 to 55 years (inclusive)~* Subjects must agree to use an adequate method of contraception from admission through 12 weeks after last administration~Exclusion Criteria:~* Evidence or history of clinically significant abnormalities or disease or chronic respiratory disorders~* Any presence or history of a clinically significant allergy including any adverse reaction to study drug~* History of drug or alcohol abuse within the past 2 years~* Smoked tobacco within the past 6 months or have a history of more than 10- pack years (number of packs smoked per day x number of years smoked)~* Donation or loss of greater than 400 mL of blood within the previous 3 months~* Have received any prescription medication within 4 weeks or investigational medication within 12 weeks of study (exception: contraceptives are permitted)~* Have received any non-prescription medication within 14 days prior to dosing (exception: paracetamol use within 2 days)~* Upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the last 3 months~* If female, nursing, lactating or pregnant~* Regular alcohol consumption in males \>21 units per week and females \>14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)~* Surgery scheduled during the study or within 3 weeks after last dose~* History of familial long QT syndrome or history of sudden death in family members aged \< 30 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- test product A (Type: EXPERIMENTAL): salmeterol and fluticasone propionate, 2 puffs
- reference product D (Type: ACTIVE_COMPARATOR): salmeterol and fluticasone propionate, 2 puffs
- test product B (Type: EXPERIMENTAL): salmeterol and fluticasone propionate, 6 puffs
- reference product E (Type: ACTIVE_COMPARATOR): salmeterol and fluticasone propionate, 6 puffs
- test product C (Type: EXPERIMENTAL): salmeterol and fluticasone propionate, 12 puffs
- reference product F (Type: ACTIVE_COMPARATOR): salmeterol and fluticasone propionate, 12 puffs

Based on this trial design, predict the completion outcome and termination type (if applicable).